AbbVie (NYSE:ABBV) is a global biopharmaceutical company known for its innovative treatments in various therapeutic areas. On March 9, 2026, William Blair reiterated its “Outperform” rating for AbbVie, emphasizing its strong position in the amylin class. At that time, AbbVie’s stock was valued at around $226.69, reflecting investor confidence in its strategic direction.
AbbVie recently announced positive topline results from its Phase 1 study of ABBV-295, a long-acting amylin analog. The study showed significant body weight reductions, with weekly dosing leading to weight loss between 7.75% and 9.79% at week 12. This promising outcome supports AbbVie’s competitive edge in the amylin class, as highlighted by William Blair.
The study also demonstrated a favorable tolerability profile for ABBV-295, with no serious adverse events reported. Mild gastrointestinal disorders were the most common adverse events, primarily occurring in the first six weeks. This safety profile strengthens AbbVie’s position in developing differentiated treatments for chronic weight management.
Despite the positive study results, AbbVie’s stock price has decreased by 2.22% to $225.01. The stock has traded between $223.23 and $230.68 today, with a market capitalization of approximately $397.86 billion. Over the past year, ABBV has seen a high of $244.81 and a low of $164.39, indicating some volatility in its stock performance.
AbbVie’s trading volume on the NYSE is about 4.05 million shares, reflecting active investor interest. The company’s ongoing development of ABBV-295, with doses ranging from 2 to 14 mg, showcases its commitment to advancing treatments in the amylin class. This focus aligns with William Blair’s “Outperform” rating, underscoring AbbVie’s potential for growth in the biopharmaceutical sector.
